Get alerts of updates about «Analysis of miRNA and DNA methylation stautus in ADHD triads»
You have subscribed to alerts about:
Analysis of miRNA and DNA methylation status in ADHD triads - project description
ADHD is a serious neurological disorder affecting 5-6 % of children in
Norway and is a major global health concern which seems to increase
in magnitude. There are indications of genetic as well as
environmental factors contributing to the development of the disorder,
and epigenetic changes have been suggested to be involved.
The main aim of this project is to investigate whether the
epigenetic status at birth is important for neurodevelopmental
disorders appearing in childhood and persisting into adulthood.
A specific aim is to identify early diagnostic biomarkers of ADHD.
The biomarkers will be important for early identification and
intervention of affected individuals, and may contribute to a
better mechanistic understanding of ADHD.
Using molecular methods, the project will characterize
epigenetic markers associated with ADHD. The biological
samples to be analyzed are cord blood samples already
collected and stored in the MoBa biobank. A triad case-control
study within MoBa will be designed, and data will be linked with
the Norwegian Patient Registry (NPR). A clinically validated
ADHD diagnosis in NPR will define the case group. Controls
matched by age and gender, negative for ADHD family history
and ADHD symptoms, will be randomly drawn from the MoBa
cohort. MiRNA and DNA methylation, as markers of epigenetic
status, will be characterized for cases and controls. Analysis of
the biological relevance of epigenetic changes for ADHD will be
See the full project description at Cristin for more information about results, researchers, contact information etc.
Nur Duale, Avdeling for molekylærbiologi, Norwegian Institute of Public Health
Ted Reichborn-Kjennerud, Avdeling for psykiske lidelser, Norwegian Institute of Public Health
Gun Peggy S. Knudsen, Helsedata og digitalisering, Norwegian Institute of Public Health
Lene Brattsti Dypås, Avdeling for molekylærbiologi, Norwegian Institute of Public Health